ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Moderna Inc

Moderna Inc (MRNA)

35.04
0.03
( 0.09% )
Updated: 11:51:42

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
30.004.905.204.755.05-0.10-2.06 %1219211:36:46
30.504.504.654.604.5750.235.26 %95311:31:58
31.004.004.255.004.1250.8019.05 %1358110:57:23
31.503.453.753.103.600.000.00 %0417-
32.003.053.304.903.1751.6048.48 %224509:50:01
32.502.572.792.692.680.249.80 %111511:30:56
33.001.982.352.262.1650.010.44 %2642711:44:18
33.501.671.851.611.76-0.06-3.59 %2045411:42:06
34.001.341.421.371.38-0.18-11.61 %57544011:46:14
34.501.021.091.081.055-0.16-12.90 %6174011:46:08
35.000.750.820.800.785-0.17-17.53 %4421,49311:51:36
35.500.570.600.600.585-0.16-21.05 %46936311:50:59
36.000.400.440.440.42-0.14-24.14 %98882511:51:13
36.500.280.310.250.295-0.18-41.86 %37236611:38:18
37.000.190.230.230.21-0.11-32.35 %1,5331,08911:47:43
37.500.140.170.170.155-0.06-26.09 %2,09524,59611:46:12
38.000.110.120.120.115-0.03-20.00 %1,68282711:48:27
38.500.070.100.070.085-0.05-41.67 %25763411:35:08
39.000.060.080.060.07-0.04-40.00 %37379611:51:35
39.500.050.060.070.055-0.02-22.22 %39528011:08:08

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
30.000.010.100.020.0550.000.00 %12,66309:35:00
30.500.010.100.030.0550.000.00 %0508-
31.000.020.030.030.025-0.02-40.00 %1357211:49:50
31.500.030.070.020.05-0.06-75.00 %563309:35:33
32.000.050.060.050.055-0.08-61.54 %1361,80911:44:05
32.500.070.100.090.085-0.06-40.00 %32293011:26:56
33.000.130.140.190.135-0.05-20.83 %2831,26511:40:59
33.500.210.230.270.22-0.08-22.86 %26883311:42:26
34.000.330.360.370.345-0.14-27.45 %19288211:47:14
34.500.500.540.580.52-0.11-15.94 %18224811:46:35
35.000.730.780.810.755-0.11-11.96 %1,83861711:46:28
35.501.021.081.081.05-0.13-10.74 %29727411:46:15
36.001.351.411.361.38-0.16-10.53 %70025711:44:04
36.501.741.801.711.77-0.42-19.72 %65453811:45:39
37.002.092.362.102.225-0.45-17.65 %1,15118011:44:08
37.502.492.771.942.63-0.62-24.22 %38221810:38:51
38.002.903.152.163.025-1.44-40.00 %543710:30:31
38.503.353.652.703.50-2.73-50.28 %21510:09:00
39.003.904.102.924.00-1.58-35.11 %24510:05:39
39.504.354.652.624.50-3.83-59.38 %13809:38:42

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RGCRegencell Bioscience Holdings Ltd
$ 10.59
(152.14%)
10.89M
HMRHeidmar Maritime Holdings Corporation
$ 4.14
(62.35%)
37.77M
SPGCSacks Parente Golf Inc
$ 0.1561
(44.54%)
310.38M
LFWDLifeward Ltd
$ 2.05
(39.46%)
93.42M
AVAHAveanna Healthcare Holdings Inc
$ 5.09
(36.10%)
1.87M
ADTXAditxt Inc
$ 0.035
(-38.38%)
86.54M
ULYUrgent ly Inc
$ 0.334
(-34.46%)
1.08M
SPHLSpringview Holdings Ltd
$ 0.8599
(-30.65%)
1.33M
KBSXFST Corporation
$ 2.15
(-30.65%)
34.01k
QRHCQuest Resource Holding Corporation
$ 2.68
(-30.39%)
322.17k
SPGCSacks Parente Golf Inc
$ 0.1561
(44.54%)
310.38M
INTCIntel Corporation
$ 23.845
(15.30%)
148.44M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 8.245
(-9.79%)
146.65M
NVDANVIDIA Corporation
$ 116.40
(0.57%)
134.5M
DMNDamon Inc
$ 0.1835
(2.69%)
100.1M

MRNA Discussion

View Posts
axelvento axelvento 1 hour ago
Scoop: White House pulls CDC director nomination

The White House is withdrawing the nomination of Dave Weldon to be the director of the Centers for Disease Control and Prevention (CDC), per a source close to Senate health committee and another source familiar.

Why it matters: The former Florida congressman was scheduled to appear before the committee this morning for a since-cancelled confirmation hearing. But his views questioning certain vaccines have garnered attention since he was nominated months ago and were sure to play a prominent role in questioning.

HHS Secretary Robert F. Kennedy Jr. himself said Weldon wasn't ready, per one of the sources.
Background: Weldon is an internal medicine doctor who served in the House of Representatives from 1995 through 2009. While in Congress, he was one of the sponsors of a bill that would have banned mercury from vaccines.

In a 2007 statement on a different bill he sponsored, Weldon wrote that "legitimate questions persist regarding the possible association between the mercury-based preservative, thimerosal, and the childhood epidemic of neurodevelopmental disorders (NDDs), including autism."
Thimerosal has been used as a preservative in vaccines, although it was taken out of childhood vaccines in 2001, per the CDC. Many studies have found no evidence of harm of thimerosal in low doses in vaccines.
Studies have also found no evidence of a connection between vaccines and autism.
Sen. Patty Murray (D-Wash.) said Weldon repeated debunked claims about vaccines in a meeting they had last month. She called on the administration to pick a nominee "who at bare minimum believes in basic science and will help lead CDC's important work to monitor and prevent deadly outbreaks."
👍️0
axelvento axelvento 2 hours ago
Going from mRNA Covid vaccines to mRNA cancer vaccines is straightforward: same fridges, same protocol, same drug, just a different patient.

In the current trials, we do a biopsy of the patient, sequence the tissue, send it to the pharmaceutical company, and they design a personalized vaccine that’s bespoke to that patient’s cancer. That vaccine is not suitable for anyone else. It’s like science fiction.

Covid Vaccines Have Paved the Way for Cancer Vaccines


https://www.wired.com/story/wired-health-lennard-lee-cancer-vaccines/
🤑 1 🤠 1
axelvento axelvento 3 hours ago
Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever received at the company.

At the helm of a two-product company that just recently rose to the big leagues in the industry, Bancel’s total pay in 2024 came in below the compensation for some Big Pharma leaders last year, such as Eli Lilly CEO David Ricks' $29.2 million or Johnson & Johnson CEO Joaquin Duato’s $24.3 million.

Still, his pay remains on an uphill trajectory and puts him roughly on par with AbbVie’s new CEO Robert Michael’s $18.5 million and above others such as Bayer CEO Bill Anderson’s 8.84 million euros ($9.6 million).

https://www.fiercepharma.com/pharma/moderna-ceo-stephane-bancel-collects-pay-bump-198m-despite-declining-revenue-and-missed
👍️0
axelvento axelvento 11 hours ago
Moderna’s mRNA-5671 (V941) encapsulates mRNA strands encoding KRAS mutations G12D, G12V, G13D, or G12C in LNPs for the treatment of nonsmall cell lung cancer, colorectal cancers, or pancreatic adenocarcinoma.

Nanoparticle Plus mRNA Attacks Pancreatic Liver Metastases in Mice

https://www.insideprecisionmedicine.com/topics/oncology/nanoparticle-plus-mrna-attacks-pancreatic-liver-metastases-in-mice/

This study demonstrates that reprogramming the immune-protective niche for metastatic pancreatic cancer can be achieved by the delivery of a STING agonist and mutant KRAS mRNA via ionizable LNPs, offering both prophylactic and therapeutic advantages.

https://pubs.acs.org/doi/10.1021/acsnano.4c14102

$MRNA
💯 1 🔝 1
axelvento axelvento 12 hours ago
Merck opens $1B Gardasil manufacturing facility in North Carolina

The complex manufactured more than 70 million doses last year, with the figure expected to increase this year, a Merck spokesperson said in an email. The campus now employs more than 1,000 people.

https://www.fiercepharma.com/manufacturing/merck-opens-1b-vaccine-manufacturing-facility-north-carolina

Merck defeats claims it should have added safety warnings to Gardasil's label, knocking out 200+ lawsuits

https://www.fiercepharma.com/pharma/merck-emerges-victorious-gardasil-safety-litigation-knocking-out-200-lawsuits-nationwide
🔜 1 😃 1
Vexari Vexari 16 hours ago
RFK Jr

On Gardasil Vaccine
💤 1 🗑️ 1
Vexari Vexari 22 hours ago
Those who have the privilege to know

Have a duty to act From a former Merk pharmaceutical rep

Brandy Vaughan Talks Vaccines

Telling all what she knows

This was done before the covid experience
👎️ 1 🗑️ 1 🤪 1
Vexari Vexari 23 hours ago
Gardasil, look here

Not over there

Study: HPV Gardasil Vaccine Linked to Decline in Fertility Rates in U.S. Women Aged 25–29
👎️ 1 💊 1 🕳️ 1 🗑️ 1
axelvento axelvento 1 day ago
Merck wins Gardasil litigation over cancer vaccine risks

On Tuesday, Merck & Co (NYSE:MRK) Inc. emerged victorious in a significant legal dispute concerning its Gardasil vaccine, which is designed to prevent cervical and other serious cancers. U.S. District Judge Kenneth Bell, presiding in Charlotte, North Carolina, dismissed more than 200 cases that were part of a consolidated multidistrict litigation.

The plaintiffs in the litigation had accused Merck (NSE:PROR) of failing to warn about potential side effects of Gardasil, specifically an increase in heart rate and ovarian issues. They contended that these warnings should have been included on the vaccine’s labels. However, Judge Bell determined that under federal law, Merck did not have the power to independently add warnings about such risks without more substantial evidence.

In his decision, Bell emphasized the importance of not deterring the use of vaccines that save lives with warnings that are not well-supported by evidence. He stated that federal law demands more than "speculative inferences" before imposing severe warnings on vaccines, which could potentially dissuade people from using them.

Merck responded to the ruling with approval, stating that they were "extremely pleased" with the outcome. The decision effectively resolves a large group of claims that had been brought against the pharmaceutical company regarding its Gardasil vaccine.

This ruling supports the position that vaccine manufacturers are not responsible for independently updating warnings on their products without the explicit direction of the Food and Drug Administration or a solid foundation of scientific proof. The dismissal of the cases underscores the legal protections in place for vaccine makers, especially when the allegations are not substantiated by robust scientific data.
👆️ 1 👍️ 1 🔜 1
axelvento axelvento 1 day ago
Moderna at Barclays Conference: Strategic Focus on Oncology and Vaccines

On Tuesday, 11 March 2025, Moderna Inc. (NASDAQ: MRNA) presented at the Barclays 27th Annual Global Healthcare Conference

https://www.investing.com/news/transcripts/moderna-at-barclays-conference-strategic-focus-on-oncology-and-vaccines-93CH-3921808
🔝 1 😀 1
Vexari Vexari 2 days ago
Can anyone on this board help to understand

Why vaccines are necessary

In one's own words

Profit aspect excluded

Would be helpful
👎️ 2 💊 1 🗑️ 1 🤪 1 🦯 1
axelvento axelvento 2 days ago
Netherlands starts bird flu vaccination program at hen farm

The Netherlands, one of the world's largest egg exporters, has launched a pilot program on a laying-hen farm to vaccinate poultry against bird flu with the aim of achieving large-scale vaccination, the government said on Monday.

"I am pleased that the poultry sector wants to take this step with me. Vaccination offers a huge opportunity to better control bird flu," said Agriculture Minister Femke Wiersma.

https://www.reuters.com/business/healthcare-pharmaceuticals/netherlands-starts-bird-flu-vaccination-program-hen-farm-2025-03-10/
💪 2 🔝 1
axelvento axelvento 2 days ago
U.S. Bird Flu Cases Continue in Poultry. Here’s Where HPAI Is Spreading in March 2025

https://www.agriculture.com/u-s-bird-flu-cases-continue-in-early-2025-here-s-where-hpai-is-spreading-in-march-11690063
👆️ 1 🙌 1
Vexari Vexari 3 days ago
Why not more on virology

How does one know

There are unicorns

Dr. Tom Cowan
👎️ 1 🕳️ 1 🗑️ 1 🚽 1 ⤵️ 1
Vexari Vexari 3 days ago
Is there more to this

RFK Jr's flipflop
👎️ 1 🕳️ 1 🗑️ 1 🚽 1 🤪 1
axelvento axelvento 4 days ago
The world should prepare now for a potential H5N1 flu pandemic, experts warn

https://cepi.net/world-should-prepare-now-potential-h5n1-flu-pandemic-experts-warn
👆️ 1 🔜 1
axelvento axelvento 7 days ago
Moderna at TD Cowen Conference: Strategic Diversification Focus $$$$$$$$$$

On Wednesday, 05 March 2025, Moderna Inc. (NASDAQ: MRNA) participated in the TD Cowen 45th Annual Healthcare Conference. The discussion, led by Tyler Van Buren from TD Cowen and Steven Hoege, President of Moderna, highlighted the company’s strategic initiatives, including product diversification and cost reduction. While Moderna remains committed to its ambitious growth plans, it also acknowledged potential challenges, such as lower COVID vaccination rates and market uncertainties.

Key Takeaways
Moderna aims for 2025 vaccine sales between $1.5 billion and $2.5 billion.
The company targets cash breakeven by 2028 through diversification and cost management.
Moderna’s product pipeline includes vaccines for RSV, flu COVID combo, norovirus, and CMV.
The individualized neoantigen therapy (INT) program is a key focus in oncology.
Moderna is prepared to advance its bird flu vaccine program as needed.
Financial Results
Moderna reiterated its 2025 sales guidance of $1.5 billion to $2.5 billion, acknowledging potential headwinds.
The company aims to achieve cash breakeven by 2028 through product launches and cost reductions.
Cash investment is projected to decrease from $6.4 billion in 2024 to $5 billion in 2026.
Operational Updates
RSV Vaccine: Contracting discussions are ongoing, with label expansion under review for high-risk 18-59 year olds.
Flu COVID Combo Vaccine: No revenue expected in 2025, with a 2026 opportunity pending efficacy data.
Norovirus Vaccine: Data expected in 2026, with trials paused due to a Guillain Barre syndrome case.
INT Program: Phase 3 melanoma trial fully enrolled, with potential approval in 2027.
Bird Flu Vaccine: Phase 3 study in the U.S. under agreement, with a proactive approach to pandemic preparedness.


Future Outlook
Product Launches: Aiming to launch 10 products in three years, with three files under FDA review.
Cost Discipline: Continued cost reductions to balance investment and revenue by 2028.
Q&A Highlights
RSV Competition: Moderna aims to offer the broadest label and strong efficacy for its RSV vaccine.
Flu Season: Challenges include declining vaccine coverage and evolving influenza viruses.
Flu COVID Combo vs. Monotherapy: Two-thirds of the population prefer the combination vaccine, though monovalent products will remain significant.



Full transcript - TD Cowen 45th Annual Healthcare Conference:

https://www.investing.com/news/transcripts/moderna-at-td-cowen-conference-strategic-diversification-focus-93CH-3913103
👆️ 1 👍️ 1 😀 2
axelvento axelvento 1 week ago
Moderna anticipates 2027 release for cancer vaccine in collaboration with Merck

https://www.investing.com/news/stock-market-news/moderna-anticipates-2027-release-for-cancer-vaccine-in-collaboration-with-merck-93CH-3909817
👆️ 1 💪 1
axelvento axelvento 1 week ago
BioNTech and Pfizer must pay damages to Moderna for the use of one of its patents in Germany. This was the ruling handed down today by Düsseldorf Regional Court in the dispute over mRNA vaccines. It is the second win for Moderna after a favourable ruling in London last year.

https://www.juve-patent.com/cases/moderna-and-freshfields-triumph-in-dusseldorf-against-biontech-and-pfizer/
💪 1 💯 1
Vexari Vexari 1 week ago
Before the measles vaccine

We had the Brady Bunch

Telling it like it is


Natural immunity from measles is lifelong

While vaccines push endless boosters

Trust your immune system

Not the pharma-driven panic

~ Dr Sherri Tenpenny ~


Fear mongering = vaccine push

Must keep those dollars rolling

From the uneducated

Must feel good

About that
👎️ 1 💊 1 🗑️ 1 🤪 1
tw0122 tw0122 1 week ago
MRNA $32s bottom feeder $$$$
👍️0
axelvento axelvento 1 week ago
insider buy$ https://www.secform4.com/filings/1682852/0001127602-25-007904.htm
👌 1 👍️ 1 💯 1
axelvento axelvento 1 week ago
Moderna CEO Stephane Bancel purchases $5 million in company stock


Bancel acquired a total of 160,314 shares of Moderna’s common stock, with purchase prices ranging from $31.04 to $31.53 per share.

https://www.investing.com/news/insider-trading-news/moderna-ceo-stephane-bancel-purchases-5-million-in-company-stock-93CH-3907204
👆️ 1 👌 1 👍️ 1
axelvento axelvento 1 week ago
-clown- RFK Jr urges Americans to get vaccinated amid measles outbreak: ‘A call to action’

https://www.hindustantimes.com/world-news/us-news/rfk-jr-urges-americans-to-get-vaccinated-amid-measles-outbreak-a-call-to-action-101740995866989.html
👍️ 1 💯 1 😀 1
axelvento axelvento 2 weeks ago
Recent advances and perspectives on the development of circular RNA cancer vaccines


https://www.nature.com/articles/s41541-025-01097-x
👆️ 1 👍️ 1 😀 1
axelvento axelvento 2 weeks ago
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Medicines-and-Healthcare-Products-Regulatory-Agency-Marketing-Authorization-in-the-UK-for-RSV-Vaccine/default.aspx
👍️ 1 💯 1 🔝 1
axelvento axelvento 2 weeks ago
Killer T cells could hold key to future 'bird flu' vaccines, study suggests

https://medicalxpress.com/news/2025-02-killer-cells-key-future-bird.html
👍️0
axelvento axelvento 2 weeks ago
Moderna to Present at Upcoming Conferences in March 2025

https://investors.modernatx.com/news/news-details/2025/Moderna-to-Present-at-Upcoming-Conferences-in-March-2025/default.aspx
👆️ 1 👍️ 1 💯 1
axelvento axelvento 2 weeks ago
From Tumor Biology to Breakthrough Therapies: The Rise of Personalized Cancer Vaccines

Notably, in the KEYNOTE-942 trial (NCT03897881) led by Jeffrey S Weber, investigators observed improved relapse-free survival (RFS) with a combination of neoantigen vaccines and pembrolizumab (Keytruda; Merck & Co), marking a significant step forward in clinical translation.1,2 This phase 2b study evaluated the efficacy and safety of mRNA-4157 (V940; Moderna and Merck), an mRNA-based individualized neoantigen therapy, combined with pembrolizumab vs pembrolizumab monotherapy in patients with resected high-risk melanoma (stage IIIB-IV). The trial enrolled 157 patients across the US and Australia, randomized 2:1 to receive either the combination therapy or monotherapy.2

At a median follow-up of 24 months, the combination therapy improved RFS (HR 0.561, P=0.053), with 18-month RFS rates of 79% vs 62% in the monotherapy group. The combination therapy was associated with more grade 3 or higher treatment-related adverse events (AEs, 25% vs 18%), though no grade 4 to 5 events were attributed to mRNA-4157. Immune-mediated AE rates were similar between groups.2

Overall, the findings suggest that mRNA-4157 plus pembrolizumab enhances RFS with a manageable safety profile, supporting the potential role of mRNA-based neoantigen therapy in the adjuvant treatment of high-risk melanoma.2

With promising results such as those observed in the KEYNOTE-942 trial, Wu explained that pharmaceutical industry has begun to provide funding for larger studies investigating neoantigen vaccines in the adjuvant and neoadjuvant settings. For example, one study (NCT05933577) investigating melanoma (nearly finished) received funding from Merck and Moderna and enrolled 1089 patients. Another study (NCT06295809) investigating cutaneous squamous cell carcinoma in the adjuvant and neoadjuvant setting (will be commencing soon) also received funding from industry and has enrolled 1000 patients. Other studies include investigations into renal cell carcinoma (RCC, NCT06307431), bladder (NCT06305767), non-small cell lung cancer (NCT06077760), and resected pancreatic ductal adenocarcinoma (NCT05968326), all in the adjuvant setting with between 200 and approximately 900 patients enrolled.1

“Now we're getting—with support from industry—not 10 or 15 patient studies, but rather on the order of 200 and even more than 1000 patients,” Wu said. “I think in the time to come, we'll be able to really, truly look at the clinical impact of such vaccines.”

https://www.pharmacytimes.com/view/from-tumor-biology-to-breakthrough-therapies-the-rise-of-personalized-cancer-vaccines
👍️ 1 🔝 1 😀 1
Vexari Vexari 2 weeks ago
What if cancer

Is a parasite
👎️ 1 🕳️ 1 🗑️ 1 🚽 1 🤪 1
axelvento axelvento 2 weeks ago
Yale doctor's use of ‘cancer vaccine' makes waves after early trials show promising results

The patients remained cancer-free for nearly three years, up until the study ended, Braun said. “We’re able to generate a long-lasting, anti-cancer immune response with the vaccine,” he said.

The next stage is a larger trial, in partnership with pharmaceutical companies Merck and Moderna, that will test the vaccine in combination with other treatments in 270 patients around the world. The first patient who enrolled in the new trial is being treated at Yale Cancer Center, Braun said.


https://www.nature.com/articles/s41586-024-08507-5

https://www.ctinsider.com/business/article/yale-cancer-vaccine-kidney-tumor-dna-research-20173018.php
👍️ 1 💯 1 🔝 1
axelvento axelvento 2 weeks ago
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

https://www.nature.com/articles/s41586-024-08508-4
👍️0
axelvento axelvento 3 weeks ago
-history repeats itself - New coronavirus with potential to cause pandemic discovered in China

The new virus is even closer related to MERS, a deadlier type of coronavirus that kills up to a third of people it infects.

HKU5-CoV-2 is strikingly similar to the pandemic virus, sparking fears that history could repeat itself just two years after the worst was declared over.



https://www.dailymail.co.uk/health/article-14421599/coronavirus-potential-cause-pandemic-discovered-china.html
👆️ 1 🤑 2
Vexari Vexari 3 weeks ago
Reading between the lines

Now up for reassessment
🕳️ 1 🗑️ 1 🚽 1 🤪 1 🫵 1
axelvento axelvento 3 weeks ago
$BNTX Experimental vaccine for common cancer shows potential in clinical trial
Some pancreatic cancer patients showed immune response to mRNA vaccine

Vinod Balachandran, MD, principal investigator of the trial and senior study author at MSK, stated his optimism about the efficacy of this treatment.

"We find that with RNA vaccine technology, we can teach the immune system to recognize pancreatic cancer, and this immune response could potentially last for many years," he said.

"The ability to trigger a robust, long-lasting immune response is a requisite feature for any cancer vaccine."

https://www.foxnews.com/health/experimental-vaccine-common-cancer-shows-potential-clinical-trial
👍️0
axelvento axelvento 3 weeks ago
Kennedy has downplayed concerns about his anti-vaccine sentiments, saying in a Senate hearing that “all of my kids are vaccinated, and I believe vaccines have a critical role in healthcare.”

FDA Issues Back-to-Back Vaccine Approvals as RFK Jr. Takes HHS Seat

As they say, history repeats itself
https://www.biospace.com/fda/fda-issues-back-to-back-vaccine-approvals-as-rfk-jr-takes-hhs-seat
👆️ 1 💯 1
axelvento axelvento 3 weeks ago
Cancer Vaccines: https://finance.yahoo.com/news/cancer-vaccines-market-track-major-180000959.html

Leading cancer vaccine companies such as IO Biotech, Merck, Moderna, Candle Therapeutics, ISA Pharmaceuticals, PDS Biotechnology, PDC*line Pharma, LG Chem, AVEO Oncology, Archival Farma, and others are developing novel cancer vaccines that can be available in the cancer vaccines market in the coming years.

Some of the key cancer vaccines in the pipeline include IO102-IO103, mRNA-4157 (V940) + KEYTRUDA, CAN-2409, Nelipepimut-S + Cemiplimab, PDS0101 + Pembrolizumab, PDC*lung01, LB-LR1109, RUTI, and others.
👆️ 1 🔜 1
axelvento axelvento 3 weeks ago
Scientists Crack The Code For Delivering MRNA Medicine To The Brain

https://scienceblog.com/scientists-crack-the-code-for-delivering-mrna-medicine-to-the-brai/
👍️ 1 💯 1 😀 1
Vexari Vexari 3 weeks ago
Unpacking the lies

~~~ That we've been fed ~~~
(3:04)

Get the truth instead

NaturalNews

To learn more, visit: https://discover.brighteon.com/unpacking-the-lies-weve-been-fed

RFK Jr.
🕳️ 1 🗑️ 1 🤥 1 🫵 1
axelvento axelvento 4 weeks ago
Moderna Earnings: Maintaining Our $102 Fair Value Estimate as Long-Term Pipeline and Strategy Intact

https://www.morningstar.com/company-reports/1264965-moderna-earnings-maintaining-our-102-fair-value-estimate-as-long-term-pipeline-and-strategy-intact?listing=0P0001F631
👆️ 1 💪 1
axelvento axelvento 4 weeks ago
Antidepressant, it's no use......it's just harmful...
$MRNA
👍️0
Vexari Vexari 4 weeks ago
Not much repeat business

In that model
👎️ 1 💊 1 🕳️ 1 🗑️ 1
Vexari Vexari 4 weeks ago
What is an Antidepressant

Why is it called for

Personalities

Can be damaging

To the hive mind
👎️ 1 🕳️ 1 🗑️ 1 🤪 1 0️⃣ 1
Vexari Vexari 4 weeks ago
How is it currently made

Take out all poisons

Starting point

RFK Jr. Outlines His Health Secretary Priorities in Post-Confirmation Interview With Fox News

‘I’m not going to take away anybody’s vaccine’

https://time.com/7222533/rfk-jr-health-human-services-secretary-confirmation-interview-fox-vaccines/
🕳️ 1 🗑️ 1 🙅 1 🚽 1 🤪 1
axelvento axelvento 4 weeks ago
Revenue: $966 million vs. $942.8 million expected
👍️0
axelvento axelvento 4 weeks ago
RFK Jr. Is Already Taking Aim at Antidepressants

Conspicuously absent was any explicit mention of childhood vaccines, which Kennedy has long railed against as the head of the anti-vaccine advocacy group Children’s Health Defense.

https://www.motherjones.com/politics/2025/02/kennedy-rfk-antidepressants-ssri-school-shootings/
👍️0
axelvento axelvento 4 weeks ago
RFK Jr. Outlines His Health Secretary Priorities in Post-Confirmation Interview With Fox News

‘I’m not going to take away anybody’s vaccine’

https://time.com/7222533/rfk-jr-health-human-services-secretary-confirmation-interview-fox-vaccines/
👍️0
axelvento axelvento 4 weeks ago
Recent Progress and Upcoming Late-Stage Pipeline Milestones

The Company remains focused on a prioritized research and development portfolio, delivering up to 10 product approvals through 2027.
👍️0
Vexari Vexari 4 weeks ago
What does the confirmation of RFK Jr. mean

~~~ For FDA and Big pharma ~~~
(23:50)

Follow the data

This is historic
- RFK Jr. Confirmed as HHS Head: A Pivotal Moment (0:01)

- Censorship and Corruption in Government Agencies (1:34)

- Proposed Reforms and Legal Actions Against the FDA (2:24)

- Impact on the Nutrition Industry and Big Pharma (7:56)

- Concerns About Heavy Metals and GMOs (12:03)

- Calls for Criminal Prosecutions and Systemic Reform (17:16)

For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews
💊 1 🕳️ 1 🗑️ 1 🫵 1
axelvento axelvento 4 weeks ago
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

Cash Position: Cash, cash equivalents and investments as of December 31, 2024, were $9.5 billion, compared to $9.2 billion as of September 30, 2024. The increase during the quarter was primarily attributable to the timing of accounts receivable collections.

https://investors.modernatx.com/news/news-details/2025/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results-and-Provides-Business-Updates/default.aspx
👆️ 1 💯 1